Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials-Reference-Cited by-同舟云学术

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials

Published:2015-12-30 Issue:12 Volume:10 Page:e0145442
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Cao Li,Yao Guang-yu,Liu Min-feng,Chen Lu-jia,Hu Xiao-lei,Ye Chang-sheng

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update;M Kaufmann;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2006

2. Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer;B Brouwers;Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine,2008

3. Locally advanced and inflammatory breast cancer;S Chia;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2008

4. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy;N Houssami;European journal of cancer (Oxford, England: 1990),2012

5. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies;A Berruti;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2014

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on “Adipose tissue radiodensity and mortality among patients with nonmetastatic breast cancer”;Clinical Nutrition;2023-07

2. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature;World Journal of Clinical Cases;2021-02-06

3. Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study;EClinicalMedicine;2020-11

4. Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance;Critical Reviews in Oncology/Hematology;2020-09

5. Clinical strategies to inhibit tumor vascularization;Tumor Vascularization;2020